Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in BFLY.
← Back to Free Index

BFLY

Analysis as of: 2026-03-06
Butterfly Network, Inc.
Butterfly Network sells handheld ultrasound devices and related cloud workflow, education, and embedded imaging software to clinicians, health systems, and partners.
ai hardware healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Portable imaging can scale if workflow sticks
The upside is credible because the product is real, gross margin is improving, and new licensing channels are emerging. The key question is whether the business becomes a durable workflow platform or remains a subscale handheld device vendor.

Analysis

Thesis
Butterfly can outgrow ordinary medtech if its single-probe architecture becomes the front end of a higher-margin workflow and embedded licensing platform; the upside is real, but the rerating requires proof that software, governance, and partner revenue become durable rather than remaining optional attach.
Last Economy Alignment
AI should expand bedside imaging by reducing training and workflow friction, and Butterfly owns differentiated hardware plus regulated workflow touchpoints. The score stops short of strongly positive because recurring software capture and partner monetization are still early, while larger vendors can bundle around it.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.5x (from 5 most recent analyses)
Reasoning
The upside case is not just more probe units. The business can earn a better valuation if enterprise workflow, subscriptions, and embedded licensing become a bigger share of revenue and make Butterfly look more like a regulated imaging platform than a subscale device vendor. That can support meaningful equity appreciation, but not a full software-style rerating unless renewal depth and partner monetization become clearly durable.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The biggest risk is not the core probe technology; it is whether Butterfly can turn product interest into sticky enterprise workflow, renewals, and repeatable partner revenue before larger imaging vendors bundle it out. Adoption friction inside health systems, compliance gating, and still-early monetization of embedded channels are the main reasons this remains a 2-5x setup rather than a clear hypergrowth winner.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.42
They control a real hardware chokepoint with a chip-based handheld ultrasound platform, and AI should make bedside imaging easier to learn and use. They only win big if that device becomes the trusted workflow and partner layer inside hospitals before larger vendors bundle around them.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$5.56
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case